ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
92,515.68
-2.09%
S&P 500
5,827.04
-1.54%
Dow Jones
41,938.45
-1.63%
US Dollar vs Yen
157.1075
-0.50%
Brent Oil
80.34
-0.34%
Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Revelation Biosciences Inc (REVB)

  7. Revelation Biosciences Inc (REVB) ニュース

REVB

Revelation Biosciences (REVB)

Revelation Biosciences Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:REVB
日付受信時刻ニュースソース見出しコード企業名
2025/01/0620 : 00Business WireNasdaq Grants Revelation Biosciences Inc. Continued ListingNASDAQ:REVBRevelation Biosciences Inc
2024/12/0322 : 38Business WireRevelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross ProceedsNASDAQ:REVBRevelation Biosciences Inc
2024/12/0220 : 00Business WireRevelation Biosciences Inc. Announces FDA Acceptance of Gemini INDNASDAQ:REVBRevelation Biosciences Inc
2024/11/1220 : 00Business WireRevelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug SupplyNASDAQ:REVBRevelation Biosciences Inc
2024/11/0906 : 15Business WireRevelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024NASDAQ:REVBRevelation Biosciences Inc
2024/09/2419 : 00Business WireRevelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10NASDAQ:REVBRevelation Biosciences Inc
2024/09/0406 : 09Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:REVBRevelation Biosciences Inc
2024/08/2705 : 25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REVBRevelation Biosciences Inc
2024/08/2206 : 30Business WireRevelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross ProceedsNASDAQ:REVBRevelation Biosciences Inc
2024/08/2005 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REVBRevelation Biosciences Inc
2024/08/1005 : 15Business WireRevelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024NASDAQ:REVBRevelation Biosciences Inc
2024/08/0305 : 11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REVBRevelation Biosciences Inc
2024/07/2913 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:REVBRevelation Biosciences Inc
2024/07/2005 : 02Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:REVBRevelation Biosciences Inc
2024/06/2422 : 00Business WireRevelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker ActivityNASDAQ:REVBRevelation Biosciences Inc
2024/06/1322 : 21Business WireRevelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of GeminiNASDAQ:REVBRevelation Biosciences Inc
2024/05/1105 : 52Business WireRevelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024NASDAQ:REVBRevelation Biosciences Inc
2024/03/2305 : 15Business WireRevelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023NASDAQ:REVBRevelation Biosciences Inc
2024/03/1322 : 00Business WireRevelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)NASDAQ:REVBRevelation Biosciences Inc
2024/03/1222 : 00Business WireRevelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth ConferenceNASDAQ:REVBRevelation Biosciences Inc
2024/03/0423 : 00Business WireRevelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of GeminiNASDAQ:REVBRevelation Biosciences Inc
2024/02/1410 : 12Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:REVBRevelation Biosciences Inc
2024/02/1323 : 00Business WireRevelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)NASDAQ:REVBRevelation Biosciences Inc
2024/02/1300 : 19Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:REVBRevelation Biosciences Inc
2024/02/0906 : 01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REVBRevelation Biosciences Inc
2024/02/0606 : 41Business WireRevelation Biosciences Inc. Announces Closing of $6.2 Million Public OfferingNASDAQ:REVBRevelation Biosciences Inc
2024/02/0306 : 06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:REVBRevelation Biosciences Inc
2024/02/0120 : 00Business WireRevelation Biosciences Inc. Announces Pricing of $6.2 Million Public OfferingNASDAQ:REVBRevelation Biosciences Inc
2024/02/0114 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:REVBRevelation Biosciences Inc
2024/01/3107 : 21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REVBRevelation Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:REVB

最近閲覧した銘柄

CCOM
SILVER
SILVER
NYSE
JPM
JP Morgan Chase
NYSE
DIS
Walt Disney
COIN
XRPUSD
Ripple
CCOM
US100
US Tech 100
NYSE
MCD
McDonalds
NASDAQ
GOOGL
Alphabet
NYSE
KO
Coca Cola
NASDAQ
TSLA
Tesla
USOTC
DTEGY
Deutsche Telekom (QX)
COIN
ADAUSD
Cardano
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
CVX
Chevron
FX
USDJPY
US Dollar vs Yen
NASDAQ
NVDA
NVIDIA
COIN
ETHUSD
Ethereum
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2025 ADVFN PLC - 全著作権所有